Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. (NCT05819398)
LUNSAYIL 1
This trial is No longer recruiting
Registration number NCT05819398
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Other
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.